已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study

阿帕蒂尼 医学 肝细胞癌 内科学 联合疗法 胃肠病学 不利影响 肿瘤科 酪氨酸激酶抑制剂 实体瘤疗效评价标准 肝癌 无进展生存期 癌症 化疗 临床研究阶段
作者
Zeran Yang,Guang Chen,Ye Cui,Xiao Guo-wen,Ting Su,Jianan Yu,Zhiyuan Zhang,Yanjing Han,Kai-Lan Yang,Long Jin
出处
期刊:Cancer Biology & Therapy [Informa]
卷期号:20 (3): 321-327 被引量:34
标识
DOI:10.1080/15384047.2018.1529099
摘要

As a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor (VEGFR2-TKI), apatinib has a certain anti-tumor effect for a variety of solid tumors. The present study evaluates its efficacy and safety in advanced hepatocellular carcinoma (HCC). In this study, 47 patients with advanced HCC were included. TACE monotherapy group included 22 patients that responded to TACE, while the group that received TACE and apatinib included 25 patients that progressed on TACE and were able to receive apatinib off label. Median overall survival (OS) was significantly improved in the apatinib plus TACE group compared with the TACE group. Similarly, apatinib in combination with TACE significantly prolonged median progression-free survival (PFS) compared with TACE monotherapy. Furthermore, there was a significant difference between combination therapy and monotherapy in both Barcelona clinic liver cancer (BCLC) B and BCLC C group. The combination therapy had a dramatic effect on OS and PFS for patients at both BCLC B and BCLC C level. The most common clinically adverse events of apatinib plus TACE group were fatigue, weight loss, hypertension, hand-foot syndrome and anorexia, which were manageable and tolerable. The efficacy analysis showed that there was no significant association of survival benefit with age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, hypertension and hand-foot syndrome. Patients with macrovascular invasion and extrahepatic invasion showed worse survival benefits. In conclusion, apatinib combined with TACE revealed certain survival benefits for HCC patients who experienced progression following TACE, which can provide a promising strategy for HCC treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xiaoyan发布了新的文献求助10
2秒前
华仔应助贪玩的一曲采纳,获得10
7秒前
7秒前
tianshicanyi发布了新的文献求助10
7秒前
天天快乐应助xiaoyan采纳,获得10
13秒前
16秒前
yfy完成签到 ,获得积分10
19秒前
19秒前
星辰大海应助YYJ采纳,获得10
20秒前
22秒前
研友_59AB85发布了新的文献求助30
22秒前
YY完成签到,获得积分0
24秒前
25秒前
英俊的铭应助陈业伟采纳,获得10
25秒前
26秒前
cccxq发布了新的文献求助10
26秒前
oldblack发布了新的文献求助10
27秒前
WZM完成签到 ,获得积分10
28秒前
30秒前
研友_59AB85完成签到,获得积分10
31秒前
32秒前
cccxq完成签到,获得积分10
37秒前
37秒前
小巧大树发布了新的文献求助30
37秒前
Riley发布了新的文献求助30
38秒前
tracy完成签到,获得积分10
45秒前
蟹黄小笼包完成签到,获得积分10
50秒前
57秒前
kid1912应助香山叶正红采纳,获得10
1分钟前
一叶知秋发布了新的文献求助10
1分钟前
风起枫落完成签到 ,获得积分10
1分钟前
CipherSage应助小白采纳,获得10
1分钟前
二十又澪完成签到,获得积分10
1分钟前
cccxq发布了新的文献求助10
1分钟前
lishui完成签到 ,获得积分10
1分钟前
1分钟前
完美世界应助一叶知秋采纳,获得10
1分钟前
1分钟前
1分钟前
平常的若雁完成签到,获得积分10
1分钟前
高分求助中
Spray / Wall-interaction Modelling by Dimensionless Data Analysis 2000
ALA生合成不全マウスでの糖代謝異常の分子機構解析 520
安全防范技术与工程 500
Mathematics and Finite Element Discretizations of Incompressible Navier—Stokes Flows 500
2024 Medicinal Chemistry Reviews 400
Актуализированная стратиграфическая схема триасовых отложений Прикаспийского региона. Объяснительная записка 360
Dictionary of socialism 350
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3192407
求助须知:如何正确求助?哪些是违规求助? 2841591
关于积分的说明 8034035
捐赠科研通 2505217
什么是DOI,文献DOI怎么找? 1338443
科研通“疑难数据库(出版商)”最低求助积分说明 638336
邀请新用户注册赠送积分活动 606881